These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16183105)

  • 1. P53 mutations in tissue from Danish ovarian cancer patients: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Kjaer SK; Blaakaer J; Christensen L; Glud E; Vuust J; Høgdall CK
    Gynecol Oncol; 2006 Jan; 100(1):76-82. PubMed ID: 16183105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a polymorphism in intron 2 of the p53 gene in ovarian cancer patients. From the Danish "Malova" Ovarian Cancer Study.
    Høgdall EV; Kjaer SK; Glud E; Christensen L; Blaakaer J; Vuust J; Bock JE; Norgaard-Pedersen B; Hogdall CK
    Anticancer Res; 2003; 23(4):3397-404. PubMed ID: 12926080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma: from the Danish "MALOVA" Ovarian Carcinoma Study.
    Høgdall EV; Ryan A; Kjaer SK; Blaakaer J; Christensen L; Bock JE; Glud E; Jacobs IJ; Høgdall CK
    Cancer; 2004 Jun; 100(11):2387-95. PubMed ID: 15160342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression level of Wilms tumor 1 (WT1) protein has limited prognostic value in epithelial ovarian cancer: from the Danish "MALOVA" ovarian cancer study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Christensen IJ; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Aug; 106(2):318-24. PubMed ID: 17540436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of p53 codon 72 polymorphisms in ovarian tumour patients and their prognostic significance in ovarian cancer patients.
    Høgdall EV; Høgdall CK; Christensen L; Glud E; Blaakaer J; Bock JE; Vuust J; Nørgaard-Pedersen B; Kjaer SK
    Anticancer Res; 2002; 22(3):1859-64. PubMed ID: 12168882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P53 mutation does not affect prognosis in ovarian epithelial malignancies.
    Fallows S; Price J; Atkinson RJ; Johnston PG; Hickey I; Russell SE
    J Pathol; 2001 May; 194(1):68-75. PubMed ID: 11329143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distant metastases in ovarian cancer: association with p53 mutations.
    Sood AK; Sorosky JI; Dolan M; Anderson B; Buller RE
    Clin Cancer Res; 1999 Sep; 5(9):2485-90. PubMed ID: 10499623
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CA125 expression pattern, prognosis and correlation with serum CA125 in ovarian tumor patients. From The Danish "MALOVA" Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Kjaerbye-Thygesen A; Gayther S; Jacobs IJ; Høgdall CK
    Gynecol Oncol; 2007 Mar; 104(3):508-15. PubMed ID: 17113137
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
    Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
    Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
    Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
    Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
    Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
    Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distribution of HER-2 overexpression in ovarian carcinoma tissue and its prognostic value in patients with ovarian carcinoma: from the Danish MALOVA Ovarian Cancer Study.
    Høgdall EV; Christensen L; Kjaer SK; Blaakaer J; Bock JE; Glud E; Nørgaard-Pedersen B; Høgdall CK
    Cancer; 2003 Jul; 98(1):66-73. PubMed ID: 12833457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas.
    Liu FS; Kohler MF; Marks JR; Bast RC; Boyd J; Berchuck A
    Obstet Gynecol; 1994 Jan; 83(1):118-24. PubMed ID: 8272291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
    Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
    Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p53 mutation is infrequent in clear cell carcinoma of the ovary.
    Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
    Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
    Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
    Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p21 expression predicts outcome in p53-null ovarian carcinoma.
    Rose SL; Goodheart MJ; DeYoung BR; Smith BJ; Buller RE
    Clin Cancer Res; 2003 Mar; 9(3):1028-32. PubMed ID: 12631602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.
    Geisler JP; Geisler HE; Miller GA; Wiemann MC; Zhou Z; Crabtree W
    Gynecol Oncol; 2000 May; 77(2):278-82. PubMed ID: 10785478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aberrations of the p53 tumor suppressor gene in human epithelial ovarian carcinoma.
    Kim JW; Cho YH; Kwon DJ; Kim TE; Park TC; Lee JM; Namkoong SE
    Gynecol Oncol; 1995 May; 57(2):199-204. PubMed ID: 7729734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.